BRPI0820504A2 - Métodos e composições para medir ativação de wnt e para tratar cânceres relacionados a wnt - Google Patents

Métodos e composições para medir ativação de wnt e para tratar cânceres relacionados a wnt

Info

Publication number
BRPI0820504A2
BRPI0820504A2 BRPI0820504-3A BRPI0820504A BRPI0820504A2 BR PI0820504 A2 BRPI0820504 A2 BR PI0820504A2 BR PI0820504 A BRPI0820504 A BR PI0820504A BR PI0820504 A2 BRPI0820504 A2 BR PI0820504A2
Authority
BR
Brazil
Prior art keywords
wnt
compositions
methods
measuring
treating
Prior art date
Application number
BRPI0820504-3A
Other languages
English (en)
Inventor
Atwood Cheung
Feng Cong
Shih-Min Huang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0820504A2 publication Critical patent/BRPI0820504A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI0820504-3A 2007-11-05 2008-11-05 Métodos e composições para medir ativação de wnt e para tratar cânceres relacionados a wnt BRPI0820504A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98545407P 2007-11-05 2007-11-05
PCT/EP2008/064987 WO2009059994A2 (en) 2007-11-05 2008-11-05 Methods and compositions for measuring wnt activation and for treating wnt-related cancers

Publications (1)

Publication Number Publication Date
BRPI0820504A2 true BRPI0820504A2 (pt) 2015-06-16

Family

ID=40626253

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820504-3A BRPI0820504A2 (pt) 2007-11-05 2008-11-05 Métodos e composições para medir ativação de wnt e para tratar cânceres relacionados a wnt

Country Status (11)

Country Link
US (1) US20100267626A1 (pt)
EP (1) EP2217223A2 (pt)
JP (1) JP2011504461A (pt)
KR (1) KR20100089869A (pt)
CN (1) CN101854924A (pt)
AU (1) AU2008324203A1 (pt)
BR (1) BRPI0820504A2 (pt)
CA (1) CA2704648A1 (pt)
EA (1) EA201000673A1 (pt)
MX (1) MX2010004982A (pt)
WO (1) WO2009059994A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US9874553B2 (en) * 2008-09-10 2018-01-23 New York University Targeted chemical high-throughput screening method
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
US8268550B2 (en) 2009-06-26 2012-09-18 Massachusetts Institute Of Technology Compositions and methods for identification of PARP function, inhibitors, and activators
WO2010151664A2 (en) 2009-06-26 2010-12-29 Massachusetts Institute Of Technology Compositions and methods for treating cancer and modulating stress granule formation
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
RU2592694C2 (ru) 2010-08-18 2016-07-27 СЭМЬЮМЕД, ЭлЭлСи Дикетоны и гидроксикетоны в качестве активатора сигнального пути катенина
EP2686347B1 (en) 2011-03-16 2018-05-02 argenx BVBA Antibodies to cd70
AU2012282076A1 (en) 2011-07-13 2014-02-27 Novartis Ag 4 - piperidinyl compounds for use as tankyrase inhibitors
EP2731942B1 (en) 2011-07-13 2015-09-23 Novartis AG Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
US9227982B2 (en) 2011-07-13 2016-01-05 Novartis Ag 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors
KR101376338B1 (ko) * 2011-09-06 2014-03-19 재단법인 제이씨비 공동생물과학연구소 스타틴계 약물 및 윈트 신호 전달 조절제를 유효성분으로 함유하는 동맥경화증 및 뇌졸중의 예방 또는 치료용 약학 조성물
EP2788378A4 (en) * 2011-12-09 2015-09-09 Oncomed Pharm Inc COMBINATION THERAPY FOR CANCER TREATMENT
EP2802658A2 (en) * 2012-01-09 2014-11-19 Novartis AG Rnai agents to treat beta-catenin related diseases
WO2013132253A1 (en) 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
EP2938745B1 (en) 2012-12-26 2020-10-07 Koninklijke Philips N.V. Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
DK2968249T3 (en) 2013-02-22 2019-03-04 Samumed Llc GAMMA DIKETONS AS WNT / BETA-CATENIN SIGNAL ROAD ACTIVATORS
EP3044221B1 (en) 2013-09-11 2018-02-21 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
MA40454B1 (fr) 2014-08-20 2020-01-31 Samumed Llc Gamma-dicétones pour le traitement et la prévention des rides et du vieillissement de la peau
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
WO2017055316A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2017055313A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2018078009A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives
WO2018078005A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
WO2018087126A1 (en) 2016-11-09 2018-05-17 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives as inhibitors of tankyrase
CN106619622A (zh) * 2016-12-14 2017-05-10 中国科学院昆明植物研究所 以丙酰胺类化合物为活性成分的药物组合物和其在制药中的应用
CA3092171C (en) 2017-10-06 2025-04-01 Eluciderm Inc. COMPOSITIONS AND METHODS OF TREATMENT OF WOUNDS
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
US20230277540A1 (en) 2020-06-09 2023-09-07 Genethon Treatment of Dilated Cardiomyopathies
KR102689750B1 (ko) 2021-04-08 2024-07-30 동아대학교 산학협력단 PFKP를 포함하는 Wnt 신호 전달로 발달된 종양 진단용 바이오마커 및 이의 용도
CN118185931B (zh) * 2022-12-14 2024-12-03 上海科技大学 一种激活Wnt信号通路的RNA编辑系统

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635642B1 (en) * 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US20120178697A9 (en) * 2003-09-22 2012-07-12 Jie Zheng Compositions and methods for the inhibition of dishevelled proteins
PL2305221T3 (pl) * 2003-12-01 2015-11-30 Kudos Pharm Ltd Inhibitory naprawy uszkodzeń DNA w leczeniu raka
WO2006006740A1 (ja) * 2004-07-14 2006-01-19 Japan Tobacco Inc. ３−アミノベンズアミド化合物及びバニロイド受容体１型(ｖｒ１)活性阻害剤
US8809287B2 (en) * 2004-11-15 2014-08-19 Icahn School Of Medicine At Mount Sinai Compositions and methods for altering Wnt autocrine signaling
WO2006097336A2 (en) * 2005-03-18 2006-09-21 The Genetics Company, Inc. A novel component of the wg/wnt signaling pathway

Also Published As

Publication number Publication date
JP2011504461A (ja) 2011-02-10
US20100267626A1 (en) 2010-10-21
CA2704648A1 (en) 2009-05-14
AU2008324203A1 (en) 2009-05-14
WO2009059994A2 (en) 2009-05-14
EA201000673A1 (ru) 2011-04-29
WO2009059994A3 (en) 2009-12-10
EP2217223A2 (en) 2010-08-18
KR20100089869A (ko) 2010-08-12
MX2010004982A (es) 2010-08-16
CN101854924A (zh) 2010-10-06

Similar Documents

Publication Publication Date Title
BRPI0820504A2 (pt) Métodos e composições para medir ativação de wnt e para tratar cânceres relacionados a wnt
EP2021192A4 (en) IMPROVED SCISSOR
BRPI0820980A2 (pt) Composições e métodos para detecção de tiabs
EP2185745A4 (en) Thermocouple
EP2063238A4 (en) SPECTROSCOPE
PT2340042E (pt) Métodos e composições para o tratamento de cancro
FI20075721L (fi) Menetelmä pyrolysoinnin toteuttamiseksi
BRPI0810108A2 (pt) Pneumático para veículos
EP2373413A4 (en) DEGRADATION CATALYST AND METHOD
EP2208072A4 (en) FORECAST PROCEDURES
EP2175251A4 (en) SPECTROSCOPE
DE112008002760A5 (de) Beleuchtungseinrichtung für Fahrzeuge
EP2283862A4 (en) ANTITUMOR AGENT
BRPI0815330A2 (pt) métodos e composições para tratar cânceres
BRPI0810207A2 (pt) Métodos e composições para o tratamento de câncer
BRPI0813842A2 (pt) Oxidação parcial de hidrocarbonetos
BRPI0918508A2 (pt) orto-aminoanilidas para o tratamento de câncer
ES1068363Y (es) Neumatico para automoviles
BR112012003278A2 (pt) métodos e composições para tratamento de leucemia
BRPI0812105A2 (pt) Neramexano para o tratamento de nistagmo
FR2928635B1 (fr) Bande support de composants
ES1065835Y (es) Caperuza para cetreria
ES1064798Y (es) Antirrobo para vehiculos
ES1065920Y (es) Nevera-termo para vehiculos
ES1064065Y (es) Obturador para pinchazos de neumaticos

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.